Synthesis and In Vitro/Ex Vivo Characterizations of Ceftriaxone-Loaded Sodium Alginate/poly(vinyl alcohol) Clay Reinforced Nanocomposites: Possible Applications in Wound Healing.
PVA
ceftriaxone
drug delivery
nanoclay
nanomaterials
sodium alginate
Journal
Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929
Informations de publication
Date de publication:
30 May 2022
30 May 2022
Historique:
received:
12
04
2022
revised:
09
05
2022
accepted:
23
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
(1) Background: Nanocomposite films are widely applied in the pharmaceutical industry (e.g., nanodrug delivery systems-NDDS). Indeed, these nanomaterials can be produced at a large industrial scale and display valuable properties (e.g., antibacterial, renewability, biodegradability, bioavailability, safety, tissue-specific targeting, and biocompatibility), which can enhance the activity of conventional marketed drugs. (2) Aim: To fabricate and investigate the in vitro properties of the antibiotic ceftriaxone sodium (CTX) once encapsulated into sodium alginate (SA)/poly(vinyl alcohol)PVA-clay reinforced nanocomposite films. (3) Methods: Different ratios of the polymers (i.e., SA, PVA) and CTX drug were used for the synthesis of nanocomposite films by solvent casting technique. Montmorillonite (MMT), modified organically, was added as a nanofiller to increase their thermal and mechanical strength. The prepared samples were physically characterized by thermogravimetric analysis (TGA), X-ray diffraction (XRD), scanning electronic microscopy (SEM), and energy-dispersive X-ray analysis (EDX). The physicochemical behavior (i.e., swelling, erosion, dissolution/drug release behavior and rat skin permeation) was also assessed. Comparisons were made with the currently marketed free CTX dosage form. (4) Results: TGA of the nanoformulation showed increased thermostability. XRD revealed its semi-crystalline nature. SEM depicted a homogeneous drug-loaded SA/PVA nanocomposite with an average size ranging between 300 and 500 nm. EDX confirmed the elemental composition and uniform distribution of mixing components. The water entrapment efficiency study showed that the highest swelling and erosion ratio is encountered with the nanoformulations S100(3) and S100D15(3). Ex vivo permeation revealed a bi-step discharge mode with an early burst liberation chased by continued drug discharge of devised nanoparticles (NPs). The dissolution studies of the drug-loaded polymer nanocomposites elicited sustained pH-dependent drug release. The cumulative drug release was the highest (90.93%) with S100D15(3). (5) Conclusion: S100D15(3) was the finest formulation. To the best of our knowledge, we also pioneered the use of solvent casting for the preparation of such nanoformulations. Polymers and reinforcing agent, concentrations and pH were rate-deterring features for the preparation of the optimized formulation. Thus, CTX-loaded SA/PVA-MMT reinforced nanocomposite appeared as a promising nanodrug delivery system (NDDS) based on its in vitro physicochemical properties.
Identifiants
pubmed: 35683183
pii: ma15113885
doi: 10.3390/ma15113885
pmc: PMC9182010
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
NeuroRx. 2005 Oct;2(4):554-71
pubmed: 16489365
Nanomaterials (Basel). 2022 Jan 06;12(2):
pubmed: 35055206
Carbohydr Polym. 2012 Sep 1;90(1):165-73
pubmed: 24751026
Int J Biol Macromol. 2020 Feb 1;144:921-931
pubmed: 31704336
Drug Deliv. 2010 Sep-Oct;17(7):508-19
pubmed: 20482471
Mater Sci Eng C Mater Biol Appl. 2015 Nov 1;56:363-73
pubmed: 26249602
AAPS PharmSciTech. 2020 Nov 16;21(8):323
pubmed: 33200249
Eur J Pharm Biopharm. 2007 Feb;65(2):204-14
pubmed: 16996255
Int J Nanomedicine. 2021 Dec 16;16:8203-8219
pubmed: 34949923
J Biomed Mater Res A. 2010 Mar 1;92(3):1131-8
pubmed: 19322877
Pharmaceutics. 2010 May 18;2(2):209-223
pubmed: 27721352
Int J Mol Sci. 2011;12(9):6040-50
pubmed: 22016643
Pharmaceutics. 2018 Sep 05;10(3):
pubmed: 30189634
Eur J Pharm Biopharm. 2007 Sep;67(2):491-7
pubmed: 17451926
Carbohydr Polym. 2017 Feb 10;157:981-990
pubmed: 27988017
Antibiotics (Basel). 2022 Mar 07;11(3):
pubmed: 35326815
Pharmaceutics. 2022 Feb 14;14(2):
pubmed: 35214141
Pharmacol Res Perspect. 2021 Aug;9(4):e00849
pubmed: 34331383
Pharmaceutics. 2021 Mar 07;13(3):
pubmed: 33799983
Int Sch Res Notices. 2014 Aug 24;2014:278173
pubmed: 27355020
J Pharm Sci. 2021 Oct;110(10):3471-3483
pubmed: 34126118
J Appl Biomater Biomech. 2004 May-Aug;2(2):74-80
pubmed: 20803440
Int J Pharm. 2008 Jul 9;359(1-2):79-86
pubmed: 18440737
Curr Pharm Des. 2016;22(22):3399-410
pubmed: 27160752
Int J Biol Macromol. 2019 Aug 15;135:1246-1251
pubmed: 31181276
Mater Sci Eng C Mater Biol Appl. 2016 Jun;63:18-29
pubmed: 27040191
Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):87-91
pubmed: 16399591
Pharmaceutics. 2019 Sep 02;11(9):
pubmed: 31480706
J Biomater Appl. 2016 Jul;31(1):3-12
pubmed: 27164869